Spero Therapeutics, Inc. (SPRO)
After hours:
| Previous Close | 1.5700 |
| Open | 1.6000 |
| Bid | 1.5800 x 400 |
| Ask | 1.6100 x 300 |
| Day's Range | 1.5350 - 1.6055 |
| 52 Week Range | 0.9900 - 1.9400 |
| Volume | |
| Avg. Volume | 312,493 |
| Market Cap | 85.839M |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 3.70 |
| EPS (TTM) | 0.4300 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireSpero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor
- GlobeNewswire
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE)
Simply Wall St.Shareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years ago
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders should be happy to see the share price up 23% in the last...
